Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02314169
Recruitment Status : Recruiting
First Posted : December 11, 2014
Last Update Posted : November 8, 2018
Information provided by (Responsible Party):
National Cancer Institute (NCI)